Increasing implants at the current rate would suit me at this stage. Thing is, when the DT trial gets underway it will increase even more.
I liked what Dr Esmore said in relation to patient sucsess. Around 85% survival rate and expected to get even better with a better understanding of selecting appropriate patients. US BTT trial will certainly be passed with flying colours at that rate.
The sales info is what is holding this stock back IMO. A more clearer picture with sales will provide the spark this stock needs.
VCR
ventracor limited
